The Bone-Modifying Agents in Metastatic Breast Cancer GUIDELINES Pocket Card™ is endorsed by the American Society of Clinical Oncology (ASCO) and based on their latest guidelines. This practical quick-reference tool includes timing of therapy, a management algorithm, FDA-approved drug list, toxicities and safety concerns—all the essential components from ASCO's full-text guidelines—and is approved by the ASCO Practice Guidelines Committee. The Bone-Modifying Agents in Metastatic Breast Cancer GUIDELINES Pocket Card™ provides all that is needed to make accurate clinical decisions at the point of care.
Indications and Timing of Therapy
Role of BMAs in the Presence of Extraskeletal Metastases
Drug Toxicities and Risks - Osteonecrosis of the Jaw
Role of BMAs in Pain Control
Current Medication Tables with Brand and Generic Names
80# Diamond Silk Cover with Satin Aqueous Coating
4.25" x 7.25"
The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. Nearly 30,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology.
The Bone-Modifying Agents in Metastatic Breast Cancer GUIDELINES digital subscription contains the same great content included in the printed pocket cards, only in a digital format. This digital subscription can be accessed anywhere, anytime, and on any device.